Dimerix Limited (ASX: DXB)

Market Cap	186.64M
Revenue (ttm)	583.48K
Net Income (ttm)	-17.08M
Shares Out	557.13M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,443,730
Open	0.335
Previous Close	0.335
Day's Range	0.300 - 0.335
52-Week Range	0.130 - 0.665
Beta	0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 24, 2024

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: DXB

Financial Performance

In 2024, Dimerix's revenue was 583,478, an increase of 1486.10% compared to the previous year's 36,787. Losses were -17.08 million, 23.7% more than in 2023.